The Latest
-
PharmaVoice 100
2024 PharmaVoice 100s: Cancer Care Visionaries
Leaders who envision a world without cancer through oncology innovation.
-
Big Pharma earnings hang hope on the next generation of blockbusters
Pfizer, J&J, Biogen and Novartis are banking on new products to make up for maturing blockbusters, but future growth is not guaranteed.
-
PharmaVoice 100
2024 PharmaVoice 100s: Clinical Trial Pros
Experts raising the bar in clinical trial design and collaboration.
-
Backlash builds against Novo’s Catalent takeover
Roche recently joined naysayers who argue the deal threatens competition in the burgeoning weight loss and diabetes drug market.
-
PharmaVoice 100
2024 PharmaVoice 100s: Cell and Gene Therapy Pioneers
Leaders molding the cutting-edge cell and gene therapy field into tomorrow's cures.
-
Deep Dive // PharmaVoice 100
The 2024 PharmaVoice 100
This year’s PharmaVoice 100 encompasses the industry’s ongoing revolutions and leaders who are not only navigating these changes, but at times, forging new paths for others to follow.
-
Q&A
How AZ’s respiratory wins are ramping up for a bigger prize in COPD
As AstraZeneca builds up indications for Fasenra, an ongoing trial will determine whether the respiratory drug can make up for past stumbles in COPD.
-
PharmaVoice 100
2024 PharmaVoice 100s: Rare Disease Warriors
Pharma pros driving drug development and access for patients with high unmet needs.
-
Where Big Pharma’s campaign cash is flowing in this election
Big Pharma CEOs are hedging all bets by supporting both sides of the aisle in the 2024 election.
-
On the front lines of the superbug war, new treatments can’t arrive soon enough
As antimicrobial resistance rises, researchers are running out of time to fight each new wave of superbugs. And the funding isn’t enough.
-
PharmaVoice 100
2024 PharmaVoice 100s: Tech and AI Wizards
Digital pioneers harnessing the data to improve pharma’s outcomes.
-
J&J’s comeback kid Spravato heads for blockbuster status
After a slow start, the novel esketamine nasal spray for depression is now J&J’s fastest-growing medication.
-
Why pharma megamergers may become a relic of the past
Despite pent up M&A demand, FTC scrutiny has had a chilling effect on pharma’s appetite for striking major deals.
-
Dengue is spreading and Sanofi is pulling the U.S. market’s only vaccine. What’s next?
As Sanofi prepares to halt production on its dengue vaccine in 2026, locally acquired infections in the U.S. are raising the alarm.
-
With activist investment rising, Pfizer’s battle with Starboard reflects the industry’s post-pandemic tumble
Pfizer’s proxy battle with Starboard has gotten messy. It’s the latest in a series of activist investor campaigns that have been on the rise in recent years.
-
PharmaVoice 100
2024 PharmaVoice 100s: Biotech Pathfinders
Leaders solving biology's toughest puzzles and driving innovation forward.
-
FDA’s GLP-1 decision kicks off ‘unprecedented’ tussle over shortage
After initially declaring the shortage of Eli Lilly’s diabetes and weight loss drugs over, the FDA changed its mind and re-opened the door for GLP-1 compounders.
-
PharmaVoice 100
2024 PharmaVoice 100s: Patient Champions
Leaders advancing health advocacy, DEI initiatives and better medicine access for patients.
-
Clinical staff that feel like ‘tech support’ — and other issues a CRO exec contends with
From tech-related challenges to an ongoing staffing crunch, Parexel’s CEO explains what the clinical trials industry is up against.
-
As new Alzheimer’s biomarkers come into play, here’s where the money is going
The Alzheimer’s Drug Discovery Foundation has its finger on the pulse of diagnostics to add precision to the next wave of therapies.
-
PharmaVoice 100
2024 PharmaVoice 100s: Cardiometabolic All-Stars
Leaders tackling long-standing health needs with new solutions.
-
Wave sees RNA editing validation in early trial results
The results provide the first clinical evidence of RNA editing, a burgeoning field that's drawn interest from biotechs and pharmaceutical companies alike.
-
Want to launch a blockbuster? An AstraZeneca exec breaks it down.
Even drugs with “blockbuster potential” often fall short of expectations. Here’s what can help a new medication pass the $1 billion mark.
-
AlphaFold’s Nobel Prize is ‘the dawn of a new era’ in mapping drug development potential
A Nobel Prize in chemistry for Google’s DeepMind protein-structure mapping is the tip of the iceberg for advances in drug discovery and development.
-
PharmaVoice 100
2024 PharmaVoice 100s: Trailblazers
Industry leaders charting new paths in science and business.